United States Food and Drug Administration (USFDA) has concluded audit at Jeevan Scientific Technology’s Bioanalytical facility in Hyderabad. The purpose of this audit was to review the BA/BE studies conducted at facilities. The auditors started the review on January 20, 2020 and completed on January 24, 2020.
The audit concluded with ‘No Observations’. This audit is specifically to access and approve the Bioequivalence studies conducted by the company for Pharmaceutical companies across the globe.
Jeevan Scientific Technology provides a range of clinical research services for healthcare/pharmaceutical industries in India and internationally. Its clinical research services comprise bio-analytical, clinical data management, biostatistics and statistical programming, medical writing, pharmacovigilance, regulatory affairs, quality assurance, and project management services, as well as clinical operation and scientific writing services.
